{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:01:43Z","timestamp":1789207303843,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ctrv.2012.02.008","type":"journal-article","created":{"date-parts":[[2012,3,18]],"date-time":"2012-03-18T01:45:34Z","timestamp":1332035134000},"page":"798-806","source":"Crossref","is-referenced-by-count":93,"title":["Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?"],"prefix":"10.1016","volume":"38","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Bundred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.A.","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.02.008_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2012.02.008_b0010","unstructured":"American Cancer Society. Breast Cancer Facts and Figures 2009\u20132010. Atlanta: American Cancer Society, Inc."},{"key":"10.1016\/j.ctrv.2012.02.008_b0015","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/jnci\/djn344","article-title":"Recent trends in breast cancer among younger women in the United States","volume":"100","author":"Brinton","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2012.02.008_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 5","key":"10.1016\/j.ctrv.2012.02.008_b0025","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Aebi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0030","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0035","unstructured":"NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer. v. 2.2011. Accessed at: www.nccn.org on November 17, 2011."},{"key":"10.1016\/j.ctrv.2012.02.008_b0040","doi-asserted-by":"crossref","unstructured":"Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009; CD004562.","DOI":"10.1002\/14651858.CD004562.pub4"},{"key":"10.1016\/j.ctrv.2012.02.008_b0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.ctrv.2012.02.008_b0050","doi-asserted-by":"crossref","first-page":"vii180","DOI":"10.1093\/annonc\/mdq422","article-title":"Prevention and treatment of side-effects of systemic treatment: bone loss","volume":"21","author":"Body","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0055","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10549-010-0899-7","article-title":"Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?","volume":"123","author":"Cameron","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.008_b0060","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/jwh.2010.2294","article-title":"The fracture risk assessment tool (FRAX((R))): applications in clinical practice","volume":"20","author":"Watts","year":"2011","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.ctrv.2012.02.008_b0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11914-010-0032-1","article-title":"The utility and limitations of FRAX: a US perspective","volume":"8","author":"Silverman","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.ctrv.2012.02.008_b0070","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2012.02.008_b0075","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.02.008_b0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s001980200035","article-title":"Fractures before menopause: a red flag for physicians","volume":"13","author":"Hosmer","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2012.02.008_b0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0020-1383(03)00117-7","article-title":"The annual incidence and seasonal variation of fractures of the distal radius in men and women over 25 years in Dorset, UK","volume":"35","author":"Thompson","year":"2004","journal-title":"Injury"},{"key":"10.1016\/j.ctrv.2012.02.008_b0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archinte.162.1.33","article-title":"Fractures between the ages of 20 and 50 years increase women\u2019s risk of subsequent fractures","volume":"162","author":"Wu","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ctrv.2012.02.008_b0095","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1210\/jc.2004-0124","article-title":"Official positions of the International Society for Clinical Densitometry","volume":"89","author":"Lewiecki","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.008_b0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference","volume":"11","author":"Baim","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.ctrv.2012.02.008_b0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.008_b0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/oxfordjournals.annonc.a057718","article-title":"The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group","volume":"1","author":"Goldhirsch","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0115","first-page":"21","article-title":"Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer","volume":"29A","author":"Reyno","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.008_b0120","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","volume":"16","author":"Levine","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0125","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/jwh.1.1999.8.949","article-title":"The risk of premature menopause induced by chemotherapy for early breast cancer","volume":"8","author":"Lower","year":"1999","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1016\/j.ctrv.2012.02.008_b0130","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-008-0071-9","article-title":"Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer","volume":"115","author":"Han","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.008_b0140","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0145","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0150","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2009.09.026","article-title":"The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer","volume":"45","author":"Hadji","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.008_b0155","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0160","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","article-title":"Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study","volume":"29","author":"Gerber","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0165","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0170","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2012.02.008_b0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0180","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0185","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0190","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0195","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2012.02.008_b0200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0205","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.008_b0210","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0215","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.008_b0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-1201-8","article-title":"Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)","volume":"125","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.008_b0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1005792830054","article-title":"Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications","volume":"43","author":"Del Mastro","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.008_b0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07357909809039747","article-title":"Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy","volume":"16","author":"Headley","year":"1998","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2012.02.008_b0235","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan Gel","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.008_b0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.008_b0245","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Overall survival with adjuvant zoledronic acid in premenopausal breast cancer patients with complete endocrine blockade \u2013 long-term results from ABCSG-12. Poster presented at: 2011 ASCO Annual Meeting; June 3\u20137, 2011; Chicago (IL). Abstract 520.","DOI":"10.1200\/jco.2011.29.15_suppl.520"},{"key":"10.1016\/j.ctrv.2012.02.008_b0250","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2010-2582","article-title":"Pretreament serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer","volume":"96","author":"Anderson","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.008_b0255","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/07357900701829777","article-title":"A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer","volume":"26","author":"Anders","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2012.02.008_b0260","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/humrep\/del201","article-title":"The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer","volume":"21","author":"Anderson","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ctrv.2012.02.008_b0265","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.24746","article-title":"Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors","volume":"116","author":"Su","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.02.008_b0270","unstructured":"Prolia 60 mg solution for injection [summary of product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; 2010."},{"key":"10.1016\/j.ctrv.2012.02.008_b0275","unstructured":"Prolia\u2122 (denosumab) injection [package insert]. Thousand Oaks, CA: Amgen Inc.; 2010."},{"key":"10.1016\/j.ctrv.2012.02.008_b0280","unstructured":"[Prolia, injection (denosumab)]. Swiss Agency for Therapeutic Products. Accessed at: <http:\/\/www.swissmedic.ch\/zulassungen\/00171\/00181\/01382\/index.html?lang=en> on November 17, 2011."},{"key":"10.1016\/j.ctrv.2012.02.008_b0285","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.02.008_b0290","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T17:48:02Z","timestamp":1561484882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0305737212000291"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}